Polymeric nanoparticles containing rapamycin and autoantigen induce antigen-specific immunological tolerance for preventing vitiligo in mice

References

• Linthorst Homan MW, Spuls PI, de Korte J, Bos JD, Sprangers MA, van der Veen JP. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol. 2009;61:411–20.
   PubMed Web of Science ®Google Scholar
• Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65:473–91. doi:10.1016/j.jaad.2010.11.061.
   PubMed Web of Science ®Google Scholar
• Grimes PE. White patches and bruised souls: advances in the pathogenesis and treatment of vitiligo. J Am Acad Dermatol. 2004;51:S5–7. doi:10.1016/j.jaad.2004.01.007.
   PubMed Web of Science ®Google Scholar
• Frisoli ML, Harris JE. Vitiligo: mechanistic insights lead to novel treatments. J Allergy Clin Immunol. 2017;140:654–62. doi:10.1016/j.jaci.2017.07.011.
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elassiuty YE, Kemp EH, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008;17:139–40; discussion 41–60.
   Web of Science ®Google Scholar
• Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clin Sci (Lond). 2011;120:99–120. doi:10.1042/CS20090603.
   PubMed Web of Science ®Google Scholar
• Lambe T, Leung JC, Bouriez-Jones T, Silver K, Makinen K, Crockford TL, Ferry H, Forrester JV, Cornall RJ. CD4 T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions. J Immunol. 2006;177:3055–62. doi:10.4049/jimmunol.177.5.3055.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–38. doi:10.1038/nature04753.
   PubMed Web of Science ®Google Scholar
• Dwivedi M, Kemp EH, Laddha NC, Mansuri MS, Weetman AP, Begum R. Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics. Autoimmun Rev. 2015;14:49–56. doi:10.1016/j.autrev.2014.10.002.
   PubMed Web of Science ®Google Scholar
• Le Poole IC, Mehrotra S. Replenishing regulatory T cells to halt depigmentation in vitiligo. J Investig Dermatol Symp Proc. 2017;18:S38–S45. doi:10.1016/j.jisp.2016.10.023.
   PubMedGoogle Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685–711. doi:10.1146/annurev.immunol.21.120601.141040.
   PubMed Web of Science ®Google Scholar
• Cronin SJ, Penninger JM. From T-cell activation signals to signaling control of anti-cancer immunity. Immunol Rev. 2007;220:151–68. doi:10.1111/j.1600-065X.2007.00570.x.
   PubMed Web of Science ®Google Scholar
• Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111–65.
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335–40. doi:10.1016/S0009-9120(98)00045-9.
   PubMed Web of Science ®Google Scholar
• Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant. 2005;5:228–36. doi:10.1046/j.1600-6143.2004.00673.x.
   PubMed Web of Science ®Google Scholar
• Mauricio MD, Guerra-Ojeda S, Marchio P, Valles SL, Aldasoro M, Escribano-Lopez I, Herance JR, Rocha M, Vila JM, Victor VM, et al. Nanoparticles in medicine: a focus on vascular oxidative stress. Oxid Med Cell Longev. 2018;2018:6231482. doi:10.1155/2018/6231482.
   PubMed Web of Science ®Google Scholar
• Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, Tsai S, Wang J, Garabatos N, Izquierdo C, et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature. 2016;530(7591):434–40. doi:10.1038/nature16962.
   PubMed Web of Science ®Google Scholar
• Maldonado RA, LaMothe RA, Ferrari JD, Zhang AH, Rossi RJ, Kolte PN, Griset AP, O’Neil C, Altreuter DH, Browning E, et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci U S A. 2015;112:E156–65. doi:10.1073/pnas.1408686111.
   PubMed Web of Science ®Google Scholar
• Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006;17:247–89. doi:10.1163/156856206775997322.
   PubMed Web of Science ®Google Scholar
• Lim J, Yeap SP, Che HX, Low SC. Characterization of magnetic nanoparticle by dynamic light scattering. Nanoscale Res Lett. 2013;8:381. doi:10.1186/1556-276X-8-381.
   PubMed Web of Science ®Google Scholar
• Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693–702. doi:10.1084/jem.176.6.1693.
   PubMed Web of Science ®Google Scholar
• Lee WT, Pasos G, Cecchini L, Mittler JN. Continued antigen stimulation is not required during CD4(+) T cell clonal expansion. J Immunol. 2002;168:1682–89. doi:10.4049/jimmunol.168.4.1682.
   PubMed Web of Science ®Google Scholar
• Dong M, Wang X, Liu J, Zhao YX, Chen XL, Li KQ, Li G. Rapamycin combined with immature dendritic cells attenuates obliterative bronchiolitis in trachea allograft rats by regulating the balance of regulatory and effector T cells. Int Arch Allergy Immunol. 2015;167:177–85. doi:10.1159/000437207.
   PubMed Web of Science ®Google Scholar
• Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol. 2007;178:7018–31. doi:10.4049/jimmunol.178.11.7018.
   PubMed Web of Science ®Google Scholar
• van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, Melief CJ, Vyth-Dreese FA, Luiten RM. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol. 2009;129(9):2220–32. doi:10.1038/jid.2009.32.
   PubMed Web of Science ®Google Scholar
• Ala Y, Pasha MK, Rao RN, Komaravalli PL, Jahan P. Association of IFN-gamma: IL-10 cytokine ratio with nonsegmental vitiligo pathogenesis. Autoimmune Dis. 2015;2015:423490. doi:10.1155/2015/423490.
   PubMed Web of Science ®Google Scholar
• Klarquist J, Denman CJ, Hernandez C, Wainwright DA, Strickland FM, Overbeck A, Mehrotra S, Nishimura MI, Le Poole IC. Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res. 2010;23:276–86. doi:10.1111/j.1755-148X.2010.00688.x.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012;3:51. doi:10.3389/fimmu.2012.00051.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Inaba K, Tarbell KV, Steinman RM. Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. Immunol Rev. 2006;212:314–29. doi:10.1111/j.0105-2896.2006.00422.x.
   PubMed Web of Science ®Google Scholar
• Monti P, Mercalli A, Leone BE, Valerio DC, Allavena P, Piemonti L. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation. 2003;75:137–45. doi:10.1097/00007890-200301150-00025.
   PubMed Web of Science ®Google Scholar
• Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177:8338–47. doi:10.4049/jimmunol.177.12.8338.
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765. doi:10.1146/annurev.immunol.19.1.683.
   PubMed Web of Science ®Google Scholar
• Hempel L, Korholz D, Bonig H, Schneider M, Klein-Vehne A, Packeisen J, et al. Interleukin-10 directly inhibits the interleukin-6 production in T-cells. Scand J Immunol. 1995;41:462–66. doi:10.1111/j.1365-3083.1995.tb03593.x.
   PubMed Web of Science ®Google Scholar